RBCK1 and diffuse large B-cell lymphoma: Moreover, targeting the HOIP-HOIL-1 interface with a synthesized peptide based on the p.Q622L polymorphism significantly decreases the NF-κB activation and increases the death of ABC DLBCL cells implicating the potential therapeutic target of LUBAC in ABC DLBCL.